Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18289
Abstract: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia (AIHA), which leads to fatigue and acrocyanosis.1– 4 Until recently, treatment of CAD was mainly based on reduction of the Bcell clone by rituximab or… read more here.
Keywords: sustained sutimlimab; sutimlimab response; agglutinin disease; trial ... See more keywords